New anti-viral drug induces significant decrease in HBsAg in hepatitis B

In this MEDtalk, Geoffrey Dusheiko, Kings College Hospital, and University College London, presents a new anti-viral drug class that may act as a new proxy for treatment and better classification of HBV patients. He also discussed the latest approaches to treating and managing HBV in this MEDtalk.